Lichtsteiner Foundation
VC Fund
Berne, Switzerland
Lichtsteiner Foundation is a VC fund in Berne focused on Biotechnology and Health Care. Lichtsteiner Foundation promotes discoveries in the field of medicine for the improvement of people’s health.
- Total investments:
- 11
- Last investment:
- Lead investor:
- 9%
Last updated:
For AI agents: llms.txt
Industries Lichtsteiner Foundation invests in
Stages Lichtsteiner Foundation invests in
Countries Lichtsteiner Foundation invests in
Round sizes
Round size
- Seed
- $1.6M–$6.8M
Investment Focus
Industry
- Biotechnology 6 (55%)
- Health Care 4 (36%)
- Medical 2 (18%)
- Life Science 2 (18%)
- Manufacturing 2 (18%)
Stage
- Seed 8 (73%)
- Series A 3 (27%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Allegria Therapeutics
|
Allegria Therapeutics operates as a biotech company. | $5.1M / Seed / Dec 11, 2025 | |
DigeHealth
|
DigeHealth's approach to monitoring gut health using bowel noises and body measurements could provide some really valuable insights into digestive well-being. | $1.6M / Seed / Dec 09, 2025 | |
Hemostod
|
HemostOD manufactures platelets on-demand from engineered stem cells. | $5.4M / Seed / Oct 01, 2025 | |
SEITO Biologics
|
SEITO Biologics is a preclinical biotechnology startup exploring innovative immunotherapies for autoimmune and chronic inflammatory illnesses. | $3.4M / Seed / Jun 11, 2025 | |
Limula
|
Limula provides a unique platform technology enabling scale out of cell therapy production. By bringing manufacturing closer to the patients, our solution will broaden access to these highly personalised treatments. Our patented solution is composed of an automation unit and single use kits, allowing healthcare providers to safely manufacture CGTin a decentralized manner. We support companies at all stages of the cell therapy life cycle, from R&D to routine production. | $6.8M / Seed / May 21, 2024 | |
Testmate Health
|
Testmate Health is a medtech startup and award-winning spin-off of University of Geneva (Switzerland). We have developed a smartphone compatible platform test kit that diagnoses any disease with an identifiable DNA or RNA sequence - without the need for a lab, providing results directly at home in minutes. Based on this platform, our firstsolution is the first rapid urine self-test for the four most common sexually transmitted diseases (STD). One million new STDs are diagnosed a day, and yet the best improvements to date still need a lab, with results taking up to 7 days to be ready. Our easy to use all-in-one-kit provides results in minutes, anywhere, at any time, and the result is scannable by a smartphone to enable people to immediately gain access to treatment – if needed. Further test-kits with other diseases are in the pipeline to empower users to skip the waiting room, and take charge of their health from home. | $6M / Seed / May 02, 2024 | |
Indivi
|
Indivi is a TechBio company developing functional biomarkers as drug development tools for neurological diseases in the form of sensor-derived measurements generated from smartphone-based assessments of cognition, motion, vision and voice. Indivi is committed to developing future-proof and transformative digital endpoints as deep phenotypinginstruments to accelerate and de-risk drug development in neurodegenerative disorders such as Parkinson’s disease, multiple sclerosis, Alzheimer’s disease and related dementias. Indivi is nurturing a unique symbiotic intersection between expert in-house knowledge and experience in data science, clinical development, signal processing engineering, and advanced analytics including computational intelligence. Through end-to-end joint endeavors with biopharmaceutical companies, Indivi is poised to continue its growth in the nascent digital endpoint industry to improve the probability of technical and regulatory success in neuroscience drug development. | Series A / Aug 31, 2022 | |
|
Indivi
|
Indivi is a TechBio company developing functional biomarkers as drug development tools for neurological diseases in the form of sensor-derived measurements generated from smartphone-based assessments of cognition, motion, vision and voice. Indivi is committed to developing future-proof and transformative digital endpoints as deep phenotypinginstruments to accelerate and de-risk drug development in neurodegenerative disorders such as Parkinson’s disease, multiple sclerosis, Alzheimer’s disease and related dementias. Indivi is nurturing a unique symbiotic intersection between expert in-house knowledge and experience in data science, clinical development, signal processing engineering, and advanced analytics including computational intelligence. Through end-to-end joint endeavors with biopharmaceutical companies, Indivi is poised to continue its growth in the nascent digital endpoint industry to improve the probability of technical and regulatory success in neuroscience drug development. | Seed / Aug 30, 2022 | |
MUVON Therapeutics
|
Muvon Therapeutics platform helps women with urinary incontinence and treats diseases based on skeletal muscle degradation, supporting them in their commitment to living a healthy life. The company's mode of contact is by mail, phone, and physical address. | Series A / May 31, 2021 | |
Microcaps
|
Microcaps develops a novel technology that enables the scalable production of precise microcapsules and microparticles based on microfluidics. Microcaps aims to provide an upscalable, fully-automated encapsulation micro-factory, that enables size control, precise dosing and increased stability of the microcapsules and microparticles. | $5.6M / Seed / Jan 26, 2021 | |
| See all 11 investments → | |||
Co-Investors
Zürcher Kantonal Bank
4 deals together
Zühlke Ventures AG
2 deals together
ALK Abelló
1 deal together
Amboy Street Ventures
1 deal together
Bernina BioInvest
1 deal together
DART Ventures
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Featured in Investor Lists
Recommended lists
FAQ
What does Lichtsteiner Foundation invest in?
Lichtsteiner Foundation invests primarily in Biotechnology, Health Care and Medical startups, most often at Seed and Series A stage. Most of the 11 investments tracked by Shizune back companies in Switzerland. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Lichtsteiner Foundation's check size?
Lichtsteiner Foundation typically joins rounds of $1.6M–$6.8M at Seed. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Lichtsteiner Foundation participates in.
When did Lichtsteiner Foundation last invest?
The most recent investment recorded for Lichtsteiner Foundation closed in Dec 2025. Shizune tracks 11 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
